Fibromyalgia and ketamine research
An educational overview of fibromyalgia, current treatment approaches, and the limited research on ketamine in selected chronic pain syndromes.
Overview
Fibromyalgia is a chronic condition marked by widespread musculoskeletal pain, fatigue, sleep disruption, and cognitive symptoms often described as 'fibro fog.' Mechanisms appear to involve central sensitization - the nervous system amplifying ordinary signals - rather than localized tissue damage.
Conventional treatment
Standard care commonly combines movement-based therapy, graded exercise, sleep optimization, cognitive behavioral therapy, and medications such as duloxetine, milnacipran, or pregabalin. No single intervention works for everyone.
Where ketamine fits
Researchers have explored NMDA receptor antagonists - including low-dose ketamine - for central sensitization syndromes. Most studies are small, short, and conducted in specialized pain settings.
What current evidence suggests
Available trials suggest some patients with fibromyalgia or related central sensitization conditions experience short-term reductions in pain intensity with low-dose ketamine, though durability and protocols are not well established.
Frequently asked questions
Does ketamine treat fibromyalgia?+
Evidence is preliminary. Ketamine is sometimes used within specialty pain programs, not as a routine treatment.
What is first-line care?+
Graded exercise, sleep optimization, cognitive behavioral therapy, and selected medications under specialist care.
Educational use only. The content on this page is provided for general educational purposes and does not constitute medical advice, diagnosis, or treatment. Ketamine and related therapies carry risks and are appropriate only under qualified medical supervision. Always consult a licensed healthcare professional about your individual situation. Information may change as research evolves.